The GLP-1 telehealth market looks completely different in 2026 than it did eighteen months ago. A wave of regulatory pressure pushed several major platforms away from compounded drugs entirely, oral formulations entered the market, and branded medication pricing shifted in ways that made some previously expensive options suddenly competitive. Before picking a clinic, you need a framework. Here it is.
The Five Criteria That Should Drive Your Decision
- Pharmacy source and drug type (compounded vs. branded FDA-approved)
- Verification of what’s actually in the vial (batch testing transparency)
- Clinical oversight depth (who reviews your labs, and how often)
- Total cash cost, all-in (not just the headline price)
- Breadth of options (do they have plan B if GLP-1 alone isn’t enough?)
Map every clinic below against those five before committing to anything.
The Clinics, Matched to the Criteria
1. FormBlends
Start here if batch-level purity data and transparent pricing matter to you. Most telehealth platforms publish either a generic certificate of analysis or nothing at all. FormBlends publishes purity percentages per product, per batch: semaglutide clears 99.1%, tirzepatide 99.3%, with high-performance liquid chromatography confirming purity, a separate mass-based method confirming the peptide’s molecular identity, and a bacterial contamination screen run on each lot. That is three independent checks, not one.
The intake is online. A licensed physician reviews it. Medications ship from a 503A compounding pharmacy that operates under FDA inspection and current good manufacturing practice standards. Flat per-vial pricing is posted before you create an account: semaglutide sits at $299, tirzepatide at $349, retatrutide at $389. No membership stacked underneath. Delivery is free and cold-chain, reaching 47 states.
The other thing that sets FormBlends apart is catalog width. Most weight-loss clinics stop at GLP-1s. Most peptide sellers operate in a research-only grey zone with no prescriber. FormBlends runs both under physician supervision: GLP-1 analogs plus recovery peptides like BPC-157 ($54), metabolic peptides like MK-677 ($79), and longevity-adjacent compounds. For non-GLP-1 peptides, human clinical evidence is limited and mostly preclinical. But if you want all options available through one licensed channel rather than piecing things together, this is the only setup like it.
Compounded medications are not FDA-approved. That is not a footnote. It is a meaningful distinction worth understanding before ordering.
2. Mochi Health
Mochi uses board-certified obesity-medicine specialists, not general practitioners pulled in to fill slots. That alone separates it from most of this list. Compounded semaglutide runs about $99 a month, tirzepatide around $199, with meaningful discounts at three and twelve-month commitments. They also work with insurance for branded drugs. If clinical rigor and cost-consciousness need to coexist, Mochi is worth a serious look.
3. Hims and Hers
After a March 2026 settlement with Novo Nordisk, Hims and Hers stopped onboarding new patients to compounded semaglutide. Branded Wegovy is now the path, at roughly $299 a month for injectable or $249 for oral, dropping dramatically with commercial insurance and the manufacturer savings card. The app is polished and onboarding is fast. Best for patients who have insurance and want a frictionless experience with branded medications.
4. Ro Body
Ro’s membership starts at about $39 for the first month, with annual prepay landing around $74 monthly. Medication is billed separately. They have a dedicated prior-authorization team, which matters more than people realize when insurance is involved and a formulary is being difficult.
5. PlushCare
Primarily prescribes branded FDA-approved drugs: Ozempic, Wegovy, Mounjaro. App membership is about $19.99 monthly, with visits and labs extra. Same-day appointments are available. Accepts insurance. Narrow catalog, but the insurance integration and appointment speed are genuine advantages.
6. Form Health
The premium end. Around $299 a month before labs and medication, you get both a physician and a registered dietitian. Best suited for well-insured patients or anyone who has tried lower-cost programs and wants more hands-on management.
7. Calibrate
Built around a 12-month commitment with heavy coaching woven into the program, not bolted on as an afterthought. The program fee is separate from medication costs. Better for patients who need structured behavior-change support alongside their prescription, and who have insurance to offset the medication side.
8. Henry Meds
Cash-pay compounded programs, often shipping within 24 to 72 hours. First-month pricing around $179 to $249. Fast and convenient. Ongoing monitoring is lighter than Mochi or Form Health. Fine if you are self-directed and just want access without hand-holding.
9. Found
Platform access from about $99 a month, medication separate. Coaching plus medication model, reasonable entry cost. Works for patients who want some structure without committing to a premium program fee.
10. Sesame
About $59 a month on an annual plan, covering telehealth visits and unlimited messaging, with medication billed separately. Marketplace pricing, no frills. If your only goal is cost-per-visit efficiency and you are comfortable managing the rest yourself, Sesame competes on price.
A Note Before You Pick
These programs vary enormously in what they actually deliver, not just what they advertise. Read the pharmacy information. Ask what testing exists on compounded batches. Understand whether your insurance will apply and what the real all-in monthly number is after medication. And whoever currently manages your health should know what you are taking. No listicle, including this one, replaces that conversation.
Sources
- FDA.gov (compounding pharmacy oversight, 503A/503B definitions, 2026 warning letter activity)
- GoodRx (branded GLP-1 pricing and savings card data)
- Drugs.com (semaglutide, tirzepatide, liraglutide prescribing information)
- Examine.com (peptide research summaries, evidence grading)
- Healthline (GLP-1 telehealth comparisons, 2025 and 2026 coverage)
- Verywell Health (obesity medicine and telehealth explainers)
- Cleveland Clinic (GLP-1 mechanism and clinical context)
- NEJM (semaglutide and tirzepatide clinical trial data, SURMOUNT and STEP series)
[internal: placement #1 | structure: Decision-guide framing, criteria-first]